维奈克拉用于伊鲁替尼或艾代拉利布治疗后进展的慢性淋巴细胞白血病患者
这项2期研究前瞻性评估维奈克拉在伊鲁替尼或艾代拉利布耐药/复发后的慢性淋巴细胞白血病患者中的疗效。36例既往接受艾代拉利布的患者中,客观缓解率为67%(24/36),12个月无进展生存率估计为79%。维奈克拉显示出有前景的临床活性和良好的耐受性。
要点
- 维奈克拉在艾代拉利布治疗后进展的慢性淋巴细胞白血病患者中客观缓解率为67%(24/36)。
- 2例达到完全缓解,1例达到完全缓解但骨髓恢复不完全。
- 未观察到肿瘤溶解综合征,3级或4级不良事件主要为血液学毒性。
核心结论
- 维奈克拉在艾代拉利布治疗后疾病进展的慢性淋巴细胞白血病患者中显示出有前景的临床活性和良好的耐受性。
研究设计与样本
- 这项2期研究前瞻性评估维奈克拉在伊鲁替尼或艾代拉利布耐药/复发后的慢性淋巴细胞白血病患者中的疗效,本文报告的是入组前最后一种B细胞受体通路抑制剂为艾代拉利布的患者。
- 维奈克拉起始剂量为每日20毫克,随后在患者内逐步增加至每日400毫克。
主要发现
- 研究入组36例既往接受艾代拉利布的患者,客观缓解率为67%(24/36)。
- 2例患者达到完全缓解,1例达到完全缓解但骨髓恢复不完全。
- 中位无进展生存期尚未达到,估计12个月无进展生存率为79%。
- 所有级别最常见的不良事件为中性粒细胞减少(56%)、腹泻(42%)、上呼吸道感染(39%)、血小板减少(36%)、恶心(31%)、疲乏(28%)、咳嗽(22%)、皮疹(22%)和贫血(22%)。
- 3级或4级不良事件主要为血液学毒性:中性粒细胞减少(50%)、血小板减少(25%)和贫血(17%);未观察到肿瘤溶解综合征。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown. Venetoclax is a selective, orally bioavailable BCL-2 inhibitor with activity in patients with CLL, including those who are heavily pretreated or have 17p deletion. This phase 2 study prospectively evaluated venetoclax in patients with R/R CLL after ibrutinib or idelalisib; here we report on patients who received idelalisib as the last BCRi before enrollment. Venetoclax was initiated at 20 mg daily, followed by intrapatient ramp-up to 400 mg daily. Primary objectives included efficacy (objective response rate [ORR]) and safety of venetoclax. The study enrolled 36 patients who previously received idelalisib (ORR, 67% [24/36]); 2 patients achieved complete remission, and 1 had complete remission with incomplete bone marrow recovery. Median progression-free survival (PFS) has not yet been reached; estimated 12-month PFS was 79%. The most common adverse events (AEs; all grades) were neutropenia (56%), diarrhea (42%), upper respiratory tract infection (39%), thrombocytopenia (36%), nausea (31%), fatigue (28%), cough (22%), rash (22%), and anemia (22%). Grade 3 or 4 AEs were primarily hematologic (neutropenia [50%], thrombocytopenia [25%], and anemia [17%]). No patients experienced tumor lysis syndrome. Venetoclax demonstrated promising clinical activity and favorable tolerability in patients with CLL whose disease progressed during or after idelalisib therapy. This trial was registered at www.clinicaltrials.gov as #NCT02141282.
引用
- Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018. PMID: 29305552. doi:10.1182/blood-2017-06-788133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。